Last reviewed · How we verify
Darunavir / Ritonavir + Tenofovir / Emtricitabine
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Darunavir / Ritonavir + Tenofovir / Emtricitabine |
|---|---|
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Darunavir and ritonavir are protease inhibitors that prevent HIV protease from cleaving viral polyproteins, blocking maturation of infectious virions. Tenofovir and emtricitabine are nucleoside/nucleotide reverse transcriptase inhibitors that prevent conversion of viral RNA to DNA. Together, this triple-class regimen suppresses HIV replication through complementary mechanisms.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Elevated liver enzymes
- Renal impairment (tenofovir-related)
- Bone density loss
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Body Composition Sub-study of the D2EFT Trial (PHASE4)
- B-free Multistage Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: